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Abstract
Experiments on human samples and on genetic animal models of Huntington's disease (HD) suggest
that a number of neuroactive metabolites in the kynurenine (KYN) pathway (KP) of the tryptophan
(TRP) catabolism may play a role in the development of HD. Our goal in this study was to assess
the concentrations of TRP, KYN, kynurenic acid and 3-hydroxykynurenine (3-OHK) in the serum
and brain of  5-month-old C57Bl/6  mice  in  the  widely used 3-nitropropionic  acid  (3-NP) toxin
model of HD. We additionally investigated the behavioral changes through open-field, rotarod and
Y-maze  tests.  Our  findings  revealed  an  increased  TRP catabolism via  the  KP as  reflected  by
elevated KYN/TRP ratios in the striatum, hippocampus, cerebellum and brainstem. As regards to
the other examined metabolites of KP, we found only a significant decrease in the 3-OHK level in
the  cerebellum  of  the  3-NP-treated  mice.  The  open-field  and  rotarod  tests  demonstrated  that
treatment with 3-NP resulted in a reduced motor ability, though this had almost totally disappeared
a week after the last injection, similarly as observed previously in most murine 3-NP studies. The
relevance of the alterations observed in our biochemical and behavioral analyses is discussed. We
propose that the identified biochemical alterations could serve as applicable therapeutic endpoints in
studies of drug effects  on delayed-type neurodegeneration in a relatively fast  and cost-effective
toxin model of HD.
Keywords: Huntington's disease, 3-nitropropionic acid, tryptophan metabolism, HPLC, behavioral 
alterations
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1. Introduction
Huntington's  disease  (HD) is  an  autosomal  dominantly inherited  progressive  neurodegenerative
disorder  which  results  in  cognitive,  psychiatric  and  motor  disturbances.  HD  is  caused  by  an
expansion of the cytosine-adenine-guanine (CAG) repeat  in the gene coding for the  N-terminal
region of the huntingtin protein (Htt),  which leads to the formation of a polyglutamine stretch.
Above 39 CAGs, there is obligatory disease development (The Huntington’s Disease Collaborative
Research Group 1993). Although the exact mechanisms through which mutant Htt (mHtt) leads to
the characteristic neuropathology are not fully understood, the potential roles of excitotoxicity and a
neuronal mitochondrial dysfunction are among the best-established concepts (Szalardy et al. 2012;
Zádori et al. 2012).
Various  evidence  suggests  that  the  involvement  of  striatal  glutamatergic  excitotoxicity  in  the
development  of  HD is  mediated  predominantly  by  the  overactivation  of  N-methyl-D-aspartate
receptors (NMDARs),  and most specifically through NR2B subunit-containing NMDARs at the
extrasynaptic sites (Milnerwood et al.  2010). In line with this, the expression of mHtt has been
shown to sensitize the NR2B subunit-containing NMDARs (Chen et al. 1999). There is evidence
indicating  that  such  excitotoxic  injury  is  mediated  at  least  in  part  by  endogenous  substances,
including certain metabolites of the kynurenine pathway (KP) of the tryptophan (TRP) metabolism
(Fig. 1; Zádori et al. 2011).
This  pathway  involves  of  a  number  of  neuroactive  compounds.  Among  them,  quinolinic  acid
(QUIN) is  a  weak NMDAR agonist  (Stone and Darlington 2002) with  demonstrated  ability to
induce excitotoxic injury, which led to QUIN toxicity being utilized as an early toxin model of HD
(Beal et al. 1986). This toxic effect of QUIN was revealed to be augmented by another deleterious
KP  metabolite,  3-hydroxykynurenine  (3-OHK),  which  can  generate  oxidative  stress  via  the
production of reactive oxygen species (ROS) (Guidetti et al. 2000). On the other hand, kynurenic
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acid (KYNA) is an NMDAR antagonist at the strychnine-insensitive glycine coagonist site (Perkins
and  Stone  1982)  and  a  weak  antagonist  on  kainate-  and  α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid-sensitive ionotropic glutamate receptors (Kessler et al. 1989). Furthermore,
its inhibitory potential on presynaptic α7-nicotinic acetylcholine receptors is proposed to be of high
relevance at physiological KYNA levels, due to the suppression of presynaptic glutamate release
(Hilmas et al. 2001). On this basis, KYNA was considered to be neuroprotective against NMDAR-
modulated  glutamatergic  excitotoxicity,  which  has  since  been  demonstrated  by  a  variety  of
experimental evidence (Miranda et al. 1997; Sinor et al. 2000).
Besides the theoretical considerations, evidence is emerging of the presence of alterations in the KP
of the TRP metabolism in tissues from HD patients and transgenic animals and in human post-
mortem HD brains (Schwarcz et al. 1988; Beal et al. 1990, 1992; Heyes et al. 1992; Pearson and
Reynolds  1992;  Jauch et  al.  1995;  Guidetti  et  al.  2004,  2006).  Briefly,  these  results  indicate  a
relative decrease in KYNA concentrations relative to the levels of toxic neuroactive kynurenines
(Zádori et al. 2011).
A decreased activity of the succinate dehydrogenase (SDH), complex II of the electron transport
chain  in  post-mortem  HD  brains  was  one  of  the  early  findings  suggestive  of  the  role  of  a
mitochondrial dysfunction in the development of HD (Stahl and Swanson 1974). Furthermore, mHtt
has been shown to be able to bind directly to the mitochondria, altering their normal function (Choo
et al. 2004). In line with the decreased SDH activity, mitochondrial II complex inhibitors such as 3-
nitropropionic acid (3-NP) or malonate have been found to be useful in the investigation of HD
through their utilization in animal toxin models (Túnez et al. 2010). The 3-NP model is frequently
applied as an easy and rapid way to study certain aspects of neurodegenerative processes in HD
(Brouillet 2014). Treatment with 3-NP evokes increases in the production of ROS and  ·NO (La
Fontaine et al. 2000) and the activation of apoptosis-related factors including caspase-3 and calpain
(Duan et al. 2000; Bizat et al. 2003a), mechanisms through which 3-NP evokes striatal lesions in
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both rodents and primates in a rather selective manner.  Several dosing regimens are applied to
evoke characteristic neuropathological and behavioral alterations in rodents (Brouillet et al. 2005).
Briefly, striatal neurodegeneration in rats occurs when the steady inhibition of SDH attains 50–60%
(Alexi et al. 1998; Brouillet et al. 1998; Blum et al. 2002; Bizat et al. 2003b). In mice, there have
been only a few studies of the dosage-related reduction in SDH activity. Lower cumulative doses
(320 mg/kg) have been shown to induce an approximately 20% reduction of enzyme activity, which
is not associated with marked striatal lesions (Fernagut et al. 2002a). However, higher cumulative
doses (400–450 mg/kg) were widely used to induce measurable striatal  lesions (Klivenyi  et  al.
2000, 2006). Accordingly, in a previous study we demonstrated a significant reduction in striatal
neuronal density via the application of unbiased semiquantitative densitometric analysis by using a
subacute dosing regimen with a cumulative dose of 500 mg/kg (Török et al. 2014).
A  number  of  publications  have  reported  3-NP-evoked  alterations  in  motor  and  cognitive
performance in rodents (Borlongan et al. 1995b; El Massioui et al. 2001; Brouillet et al. 2005; Li et
al.  2009).  The  described  alterations  in  motor  functioning  are  highly  reminiscent  of  those
characteristic of human juvenile HD, such as rigidity, bradykinesia, dystonia and gait disturbances
(Nance and Myers 2001). Although it seems clear that higher cumulative doses of 3-NP cause motor
and cognitive impairments, the motor dysfunctions observed undergo a considerable amelioration
after the cessation of toxin administration (El Massioui et al. 2001; Fernagut et al. 2002b; Li et al.
2009). Early studies raised the possibility that the KP is altered in 3-NP models (Csillik et al. 2002;
Luchowski et al. 2002), but this has not yet been further investigated.
The aims of the present study were a delayed assessment of the TRP metabolism with regard to
certain metabolites of the KP following subacute 3-NP treatment, and a comparison of the time-
course of the toxin-induced behavioral alterations with the data available from the literature.
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2. Materials and methods
2.1. Animals and 3-NP treatment
We used 30 5-month-old male C57Bl/6 mice in this study. The animals were housed in cages under
standard  conditions  with  a  12-12-h  light-dark  cycle  and  free  access  to  food  and  water.  The
experiments were carried out  in  accordance with the European Communities  Council  Directive
(86/609/EEC) and were approved by the local animal care committee. The animals were randomly
divided into two groups (n = 16 and n = 14, respectively). In the first group, 3-NP (Sigma-Aldrich,
Saint Louis, MO, USA; dissolved in phosphate-buffered saline (PBS), pH adjusted to 7.4) was
administered in a subacute dosing regimen as reported previously (Török et al. 2014), with twice
daily intraperitoneal (i.p.) injections (50 mg/kg each) for 5 consecutive days. The second group
served as the vehicle-injected control.
2.2. Behavioral assessment
2.2.1. Open-field test
Spontaneous locomotor and exploratory activities of the animals were assessed with the open-field
paradigm. The first analysis was performed 3 days before the beginning of 3-NP administration to
exclude any spontaneous difference between the randomly distributed animals.  The second and
third analyses were performed on the 3rd and the 11th day subsequent to the last day of the toxin
regimen. The tests were performed at the same time of day to avoid possible changes due to the
diurnal rhythm. Each mouse was placed in the center of an open-field motimeter box measuring
48*48*40  cm  for  15-min  tracking  periods  (analyzed  in  three  5-min  periods).  The  movement
patterns of the animals were tracked and recorded with the Conducta 1.0 system, with the use of
infrared beams (Experimetria Ltd., Budapest, Hungary). The ambulation distance, the time spent in
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immobility and the total time spent with consecutive rearings were the parameters used to assess the
motor  and  exploratory  characteristics  of  the  mice.  The  grid  and  the  walls  of  the  setup  were
thoroughly wiped with a cloth containing ethanol solution 70 v/v% after each session to prevent any
bias from olfactory cues.
2.2.2. Rotarod test
The rotarod test was applied to characterize the effects of 3-NP on motor coordination. The animals
were trained on the rotarod for a 3-session period for 5 min on 2 consecutive days prior to the first
test day. On the first and second days of the training sessions, a constant speed of 5 and 10 rpm,
respectively, was used. Following the training sessions, the first test was performed prior to the first
3-NP injection in order to exclude any inborn difference between the randomly distributed 2 groups.
During the tracking sessions on the test days, an accelerating speed profile from 1 rpm to 30 rpm
was set for a 5-min tracking period. The performance of each mouse was measured three times;
resting periods of 30 min were allowed between consecutive tracking sessions. The latency to fall
values were recorded with the TSE Rotarod Advanced system (TSE Systems International Group,
Frankfurt am Main, Germany). The average latency to fall values were used for the comparative
analyses. The second, third and fourth tests were performed 2 h following the second 3-NP injection
and on the 1st and 10th days following the last 3-NP administration, respectively. On the day before
the respective test days, a 3-session retraining at 10 rpm for 5-min with 30-min resting periods was
carried out to enable the animals to recall the rotarod experience. The rods and the separating walls
were thoroughly wiped with  a  cloth  containing ethanol  solution 70 v/v% after  each session  to
prevent any bias from olfactory cues.
2.2.3. Y-maze test
An asymmetric Y-maze paradigm was applied to assess the short-term spatial memory of the mice.
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The  Y-shaped  translucent  maze  was  placed  on  a  black  board  enclosed  by black  walls,  which
prevented any view of the external environment. Unique visual cues were placed around the three
arms of the maze. The test was performed on the 9 th day after the end of the toxin regimen. The
animals were first placed into the labyrinth and allowed to explore the common arm and only 1 of
the 2 shorter arms of the maze until each mouse had spent a total of 2 min in the open short arm.
After the session of acquisition, the mice were returned to their home cages for 30 min. In the trial
of recall, the animals were free to enter all arms, and the tracking was stopped after a total of 2 min
had been spent  inside  the  2  short  arms.  The exploratory activity  of  the  mice  was  tracked and
recorded with the SMART v2.5 system (Panlab, Barcelona, Spain). For evaluation, the recognition
indices of the time spent and the distances travelled in the novel arm of interest were used. The
recognition index was calculated via the following formula, where P is the examined parameter:
recognition index = Pnovel arm / (Pnovel arm + Pknown arm)
The side of the novel arm was randomly distributed in each group, and the board and walls of the
setup were thoroughly wiped with a cloth containing ethanol solution 70 v/v% after each session to
prevent any bias from olfactory cues.
2.3. High-performance liquid chromatography (HPLC)
2.3.1. Sample preparation
The  investigated  reference  compounds  (L-TRP,  L-KYN-sulfate,  KYNA  and  3-OHK),  the
substances used as internal standards (3-nitro-L-tyrosine (3-NLT) and isoproterenol (IPR)),  zinc
acetate  dihydrate  and sodium octylsulfate  were purchased from Sigma-Aldrich (St.  Louis,  MO,
USA). Acetonitrile and perchloric acid (PCA) were purchased from Scharlau (Barcelona, Spain),
and  acetic  acid,  phosphoric  acid,  sodium  dihydrogenophosphate and  disodium
ethylenediaminetetraacetate were purchased from VWR International (Radnar, PA, USA).
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On the 18th day of the experiment (12 days after the last 3-NP injection), the mice were deeply
anesthetized with isoflurane (Forane®; Abott Laboratories Hungary Ltd., Budapest, Hungary). After
thoracotomy,  0.3–0.7  ml  venous  blood  was  obtained  from  the  right  ventricle  by  intracardial
puncture, followed by perfusion with artificial cerebrospinal fluid (composition in mM: 122 NaCl, 3
KCl, 1 Na2SO4, 1.25 KH2PO4, 10 D-glucose*H2O, 1 MgCl2*6H2O, 2 CaCl2*2H2O, 6 NaHCO3) for 2
min by an automatic peristaltic pump. The blood samples were left to coagulate for 30 min, and
were  then  centrifuged  for  10  min  at  12,000  rpm.  The  supernatant  sera  were  pipetted  into
polypropylene Eppendorf tubes and stored at -80 °C until further sample handling. After perfusion,
the brains were rapidly removed on ice and stored at -80 °C until analysis. Before analysis, the brain
samples were weighed and then sonicated in an ice-cooled solution (250 µl) containing 2.5 w/w%
PCA with 2 µM 3-NLT and 600 nM IPR as internal standards. The samples were next centrifuged at
12,000 rpm for 10 min at 4 °C, and the supernatants were collected.
Before analysis, the serum samples were thawed and, after a brief vortex 200 µl of serum sample
was 'shot' onto 200 µl of precipitation solvent (containing 5 w/w% PCA with 4 µM 3-NLT and 2
µM IPR as internal standards). The samples were subsequently centrifuged at 12,000 rpm for 10
min at 4 °C, and the supernatants were collected.
2.3.2. Measurement of TRP, KYN and KYNA
The TRP, KYN and KYNA concentrations of the samples were quantified by a slight modification
of the method of Hervé et al. (Hervé et al. 1996), with the use of an Agilent 1100 HPLC system
(Agilent Technologies, Santa Clara, CA, USA). The system was equipped with a fluorescent and a
UV detector, the fluorescent detector was set at excitation and emission wavelengths of 344 nm and
398 nm for the determination of KYNA and TRP, and the UV detector was set at 365 nm for the
determination  of  KYN  and  the  internal  standard  3-NLT.  Chromatographic  separations  were
performed  on  an  Onyx  Monolithic  C18  column,  100  mm  x  4.6  mm  I.D.  (Phenomenex  Inc.,
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Torrance, CA, USA) after passage through a Hypersil ODS pre-column, 20×2.1 mm I.D., 5 μm
particle size (Agilent Technologies, Santa Clara, CA, USA) with a mobile phase composition of 0.2
M zinc acetate/ACN = 95/5 (v/v%) with the pH adjusted to 6.2 with glacial acetic acid, applying
isocratic elution. The flow rate and the injection volume were 1.5 ml/min and 50 µl, respectively.
The peaks of the different compounds obtained during chromatographic analysis are presented in
Fig. 2.
2.3.3. Measurement of 3-OHK
For determination of the concentrations of 3-OHK and its internal standard (IPR), we applied the
Agilent  1100  HPLC  system  equipped  with  Model  105  electrochemical  detector  (Precision
Instruments, Marseille, France). In brief, the working potential of the detector was set at +650 mV,
using a glassy carbon electrode and an Ag/AgCl reference electrode. The mobile phase containing
sodium  octylsulfate  (2.8  mM),  sodium  dihydrogenophosphate  (75  mM)  and  disodium
ethylenediaminetetraacetate (100 µM) was supplemented with acetonitrile (5 v/v%) and the pH was
adjusted to 3.0 with phosphoric acid (85 w/w%). The mobile phase was delivered at a rate of 1
ml/min at 40 °C onto the reversed-phase column (HR-80 C18, 80×4.6mm, 3-μm particle size; ESA
Biosciences, Chelmsford, MA, USA) after passage through a pre-column (Hypersil ODS, 20×2.1
mm, 5-μm particle size; Agilent Technologies, Santa Clara, CA, USA). Ten-microliter aliquots were
injected  by the  auto-sampler  with  the  cooling  module  set  at  4  °C.  The  peaks  of  the  different
compounds obtained during chromatographic analysis are presented in Fig. 2.
2.4. HPLC method validation
2.4.1. Calibration curve and linearity
Calibrants were prepared at 6 different concentration levels, from 0.1 to 50 µM, 0.05 to 5 µM, 1 to
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100 nM, 10 to 200 nM, 0.5 to 7.5 µM and 25 to 600 nM for TRP, KYN, KYNA, 3-OHK and the
internal standards, 3-NLT and IPR, respectively.  Three parallel  injections of each solution were
made under the chromatographic conditions described above. The peak area responses were plotted
against the corresponding concentration, and the linear regression computations were carried out by
the least square method with the freely available R software (R Development Core Team 2002).
Very good linearity was observed throughout the investigated concentration ranges for TRP, KYNA,
KYN, 3-OHK and the internal standards when either fluorescence, UV or electrochemical detection
was applied.
2.4.2. Selectivity
The selectivity of the method was checked by comparing the chromatograms of TRP, KYN, KYNA,
3-OHK and the internal standards for blank serum and homogenized brain samples and those for
spiked  serum and homogenized brain  samples.  All  compounds  could  be  detected  in  their  own
selected chromatograms without any significant interference.
2.4.3. LOD and LLOQ
The limit of detection (LOD) and the lower limit of quantification (LLOQ) were determined via the
signal-to-noise ratio with a threshold of 3 and 10, respectively, according to the ICH guidelines
(ICH 1995). The LOD for brain samples was 10, 40, 0.4 and 10 nM, while LLOQ was 20, 130, 1
and 30 nM for TRP, KYN, KYNA, and 3-OHK, respectively. The LOD for the serum samples was
15, 100, 1 and 10 nM, while LLOQ was 35, 275, 3.75 and 30 nM for TRP, KYN, KYNA and 3-
OHK, respectively.
2.4.4. Precision
Replicate HPLC analysis showed that the relative standard deviation was ≤ 2.2% for the peak area
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response and ≤ 0.1% for the retention time for TRP, KYN and KYNA, whereas in the case of 3-
OHK the relative standard deviation was ≤ 8.6% for the peak area response and ≤ 0.3% for the
retention time.
2.4.5. Recovery
The relative recoveries were estimated by measuring spiked samples of TRP, KYN, KYNA and 3-
OHK at 2 concentrations with 3 replicates of each. No significant differences were observed for the
lower and higher concentrations. The recoveries for the brain samples were 86 to 91%, 98 to 100%,
82 to 92% and 69 to 74% for TRP, KYN, KYNA and 3-OHK, respectively. The recoveries for the
serum samples ranged from 77 to 90%, 77 to 82%, 103 to 108% and 28 to 34% for TRP, KYN,
KYNA and 3-OHK, respectively. 
2.5. Statistics
All statistical analyses were performed with the use of the R software (R Development Core Team
2002). We first checked the distribution of data populations with the Shapiro-Wilk test, and we also
performed the Levene test for analysis of the homogeneity of variances. In the behavioral analyses,
all the data exhibited normal distribution and equal variances were assumed, and we therefore used
the independent t-test to compare the 2 groups. As a consequence of the multiple comparisons of the
same 2 groups, the necessary corrections were carried out in p values according to the Bonferroni
method. In the case of the HPLC analyses, due to the necessity of a large number of comparisons of
data from the 2 groups obtained via a single measurement,  two-sample t-tests via Monte-Carlo
permutation (with 10,000 random permutations) were applied. We rejected the null hypothesis when
the corrected p values were < 0.05, and in such cases the differences were considered significant.
Data with Gaussian or non-Gaussian distributions were plotted as means (± S.E.M.) or medians
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(and interquartile range), respectively.
3. Results
3.1 Behavioral assessment
Our results demonstrated a significant decrease in the latency to fall period in the 3-NP-treated
animals (35.33 ± 6.97 s; p < 0.001, independent t-test) in the rotarod test 1 day after the last toxin
injection in the subacute treatment regime as compared with the control group (126.34 ± 8.08 s). 10
days after the last injection, this difference had disappeared (p = 0.16, independent t-test; Fig. 3A).
In the Y-maze test, there was no difference between the groups 9 days after the last injection (p =
0.37, independent t-test; Fig. 3B). In the open-field test performed 3 days after the last injection, a
significant  decrease  was  observed  in  the  ambulation  distance  during  the  total  15-min  tracking
period (3-NP: 3203.2 ± 249.9 cm; control: 4874.9 ± 409.6 cm; p = 0.003, independent t-test; Fig.
3C) including that in the last 5-min period (3-NP: 950.4 ± 108.6 cm; control: 1359.5 ± 116 cm; p =
0.028, independent t-test; Fig. 3E). However, 11 days after the last 3-NP injection, the difference
was significant only as regards the last 5-min period (3-NP: 985.2 ± 69.9 cm; control: 1417.1 ± 106
cm; p = 0.001, independent t-test; Fig. 3C). No difference in rearing time was detected between the
groups either in the total 15-min (Fig. 3D) or in the last 5-min (Fig. 3F) tracking period.
3.2. HPLC analysis
As shown in Table 1, no difference was found in the KYNA concentration in the serum or in the
investigated brain regions of the toxin-treated and control mice 12 days after the last injection, and
there was no significant difference between the TRP levels of the serum samples of the toxin-treated
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and control mice, whereas in the case of KYN, a significant difference was detected in the cortex
(2,679 ± 110 pmol/g wet weight (ww);  p = 0.017,  permutation test) relative to the control value
(3,110 ± 112 pmol/g ww). However, significantly decreased TRP levels were found in the striatum
(19,530  (17,700–20,440)  pmol/g  ww;  p =  0.0002,  permutation  test),  cortex  (14,360  (13,540–
16,300) pmol/g ww;  p = 0.003, permutation test), hippocampus (16,550 (14,790–17,580) pmol/g
ww;  p = 0.006, permutation test), cerebellum (14,930 (14,210–16,260) pmol/g ww;  p = 0.0002,
permutation test) and brainstem (12,740 (12,280–14,100) pmol/g ww; p = 0.0004, permutation test)
of  3-NP-treated mice as  compared with the controls (27,950 (23,820–35,700);  22,860 (17,260–
28,430);  26,590 (18,020–30,730);  24,810 (17,630–28,510);  20,960 (15,920–29,890)  pmol/g ww,
respectively).  The observed decreases in TRP level were generally associated with an increased
KYN/TRP ratio, an index widely used to assess the metabolic activity of KP. Indeed, a significant
increase in KYN/TRP ratio were observed in the striatum (0.156 ± 0.014; p = 0.008, permutation
test),  hippocampus (0.158 ± 0.008;  p = 0.023, permutation test),  cerebellum (0.166 ± 0.01;  p =
0.008, permutation test) and brainstem (0.166 ± 0.008;  p = 0.009, permutation test) as compared
with the control values (0.102 ± 0.011; 0.122 ± 0.011; 0.129 ± 0.007; 0.117 ± 0.013, respectively;
Fig. 4); however, the difference in the cortex did not reach statistical significance. No difference in
the KYN/TRP ratio was observed in the serum. Additionally, a significant decrease in 3-OHK level
was observed in the cerebellum (to below the LOD; p = 0.005, permutation test) in the 3-NP-treated
mice in comparison with the control value (66.84 (28.99–97.64) pmol/g ww), but not in the other
brain regions.
4. Discussion
Although  HD  is  a  rare  condition,  it  serves  as  a  prototype  of  monogenically  determined,  but
multifactorially  affected  neurodegenerative  disorders  (Kim  and  Fung  2014).  Study  of  the
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pathogenetic process in animal models of HD could therefore provide a valuable tool for insight
into the general neurodegenerative process, yielding a possibility of finding promising targets for
drug development.
From this respect,  genetic rodent models are optimal tools for the study of HD in view of the
possible  molecular  and  genetic  translatability  to  humans  (Ramaswamy et  al.  2007).  However,
animal genetic models also fail to demonstrate the pathological alterations characteristic of human
HD  completely.  Furthermore,  the  relatively  long  duration  of  disease  development  may  be  a
disadvantage  in  studies  in  which  the  therapeutic  effects  of  potential  neuroprotective  agents  are
assessed.
Before genetic models were established, a number of toxin-based models were utilized to study the
neurodegenerative processes in HD, which may still be a rapid and cost-effective way of screening
the therapeutic effects of potential drug candidates prior to the costly and demanding application of
genetic  models.  These  inhibitors  of  the  mitochondrial  functions  are  widely used  to  model  the
mitochondrial dysfunction in HD (Browne 2008).
SDH, the enzyme of complex II in the mitochondrial electron transport chain (Alston et al. 1977), is
reversibly and irreversibly inhibited by malonate and 3-NP, respectively, toxins which have proved
to furnish applicable phenotypic models of HD (Beal and Brouillet 1993; Beal et al. 1993). 3-NP is
currently the toxin most widely used to study certain neuropathological aspects of the disease.
The  consecutive  or  continual  administration  of  3-NP  to  rodents  (i.p.  or  subcutaneously,
respectively) leads to bilateral dystonia, rigidity, gait disturbances and uncoordinated movements.
At  lower  cumulative  doses  of  3-NP (<60 mg/kg),  motor  symptoms have  been described to  be
manifested in mild movement disturbances, such as slowness and a subtle wobbling gait. However,
some authors have also reported early-stage hyperactivity at lower cumulative doses (<40 mg/kg)
(Borlongan  et  al.  1995a).  When  the  cumulative  dose  is  elevated  up  to  80  mg/kg,  the  general
weakness becomes more marked and dystonia develops, the latter being particularly pronounced in
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the hind-limbs at this dose, and appearing soon after toxin administration (Brouillet 2014). A further
elevation of the cumulative dose (>100 mg/kg) results in more expressed weakness and rigidity
(Brouillet 2014). However, subsequent to the termination of the subacute toxin regimen in mice in
the widely-applied experimental setup (as used in the current study),  the detected alterations in
motor functioning tend to abate and then cease (Fernagut et al. 2002a, 2002b; Li et al. 2009). It
should  be  noted,  however,  that  the  extended  application  of  3-NP  in  a  considerably  higher
cumulative dose resulted in persistent locomotor deficits in one study on mice (Stefanova et al.
2003). Studies involving 3-NP intoxication in rats yielded rather inconclusive results in terms of a
persistent motor dysfunction (Teunissen et al. 2001; Tasset et al. 2012).
As regards a cognitive impairment, rats treated with a cumulative dose of 190 mg/kg demonstrated
a severely decreased memory function in a fear-associated memory test (a passive avoidance task)
and a perceptual-learning task (an attentional set-shifting task) (El Massioui et al. 2001). However,
in  a  simple  2-trial  Y-maze  paradigm,  performed  on  the  15th day  after  termination  of  the
administration of 3-NP to mice (in a cumulative dose of 320 mg/kg), the intoxicated animals did not
display any 3-NP-induced memory impairment (Li et al. 2009).
The above observations in mice were confirmed by our findings, i.e. most of the behavioral changes
disappeared  (i.e. the latency to fall,  tested by rotarod; and the ambulation distance, tested in an
open-field)  or could not be detected (the recognition index, tested with the Y-maze test) 11 days
after the last injection. The lack of difference in cognitive performance was not influenced by any
incidental difference in locomotor acitivity, because we did not observe any significant difference in
the total ambulation distance within the Y-maze (not shown). It is noteworthy, however, that we
observed a significant reduction in the ambulation distance parameter in the last 5 min of the open-
field test in the toxin-treated animals as compared with the controls, which may reflect a slight
persistent behavioral dysfunction.
As  concerns  to  the  previously  observed  alterations  in  the  TRP metabolism  in  transgenic  HD
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animals, the 3-OHK and KYNA levels were reported to be elevated in the striatum and cortex of a
heterozygous transgenic mouse (FVB/N background, 89 CAG repeats, 12-15 months of age) model
of  HD (Guidetti  et  al.  2000).  Another  study involving the  R6/2  mouse model  of  HD revealed
increased kynurenine 3-monooxygenase activity in the striatum, cortex and cerebellum of 6-12-
week-old  animals,  while  the  3-hydroxyanthranilic  acid  oxygenase,  kynurenine  aminotransferase
(KAT)-I and KAT-II activities (catalyzing the conversion of KYN to KYNA) in the cortex and
cerebellum were unchanged. An elevated synthesis  of 3-OHK was found in the striatum and a
decreased kynureninase activity in the striatum and cortex of 4-12-week-old animals, but not in the
cerebellum.  Other  investigated  compounds  (KYN,  KYNA  and  QUIN)  did  not  display  any
difference (Sathyasaikumar et al. 2010). In the R6/2 model, enhanced 3-OHK concentrations were
observed in the striatum, cortex and cerebellum of 4-12-week-old animals, but no difference was
found in younger mice (Guidetti et al. 2006). In the HdhQ92 and HdhQ111 models, 5-17-month-old
animals demonstrated increased levels of 3-OHK in the striatum, cortex and cerebellum, and of
QUIN in the striatum and cortex, whereas there were no differences in younger animals (Guidetti et
al. 2006). In the YAC128 model, the 3-OHK concentrations were increased in the striatum, cortex
and cerebellum of 5-12-month-old mice, while the QUIN levels were elevated only in the striatum
and cortex of 8-12-month-old animals (Guidetti et al. 2006). In the same YAC128 mouse model, the
striatal expression of indoleamine 2,3-dioxygenase (IDO)-1 (probably the most important enzyme
participating in the TRP catabolism in the brain), was found to be up-regulated, whereas IDO-2 and
tryptophan  2,3-dioxygenase  did  not  undergo  any  significant  change.  As  concerns  metabolite
concentrations, the levels of TRP and 3-OHK proved to be decreased in the striatum of 3-month-old
animals. However, no difference in TRP level was found in 12-month-old mice, while 3-OHK and
KYN were significantly elevated in the striatum. The KYNA and QUIN concentrations did not
change  in  either  group  (Mazarei  et  al.  2013).  Studies  on  the  hippocampus  did  not  indicate
significant difference in any examined model or age group (Guidetti et al. 2006).
17
In contrast with genetic models, there are no available published data on the effects of 3-NP toxicity
on the concentrations of TRP and KP metabolites under in vivo conditions in mice. One of the two
studies of the effects of the chronic treatment of rats with 3-NP demonstrated a significant decrease
in the amount of KAT-I-immunoreactive cells, predominantly in the striatum (Csillik et al. 2002).
The other study on  ex vivo  rat  cortical  slices, showed that 3-NP dose-dependently inhibited the
production  of  KYNA and  led  to  decreased  KAT-I  and  KAT-II  activities  in  the  cortical  tissue
homogenates (Luchowski et al.  2002).  No murine studies have been conducted previously to
assess the effects of in vivo applied 3-NP on the KP metabolism at the metabolite level per se,
and there have been no studies of KP alterations due to 3-NP intoxication in the serum, which
would allow conclusions as to the possible effects of systemic KP alterations within the CNS.
We have now quantitatively assessed the levels of 4 KP metabolites in the striatum, cortex,
hippocampus, cerebellum and brainstem of mice, with a relatively high number of animals
per group (n = 14-16).
Our findings indicated a decreased TRP level in association with an increased KYN/TRP ratio in
most  of  the  examined  brain  regions  of  C57Bl/6  mice  treated  with  3-NP,  and  also  a  reduced
concentration of 3-OHK in the cerebellum. It is noteworthy that we did not detect any significant
difference  in  serum samples,  which  suggests  that  the  observed  alterations  are  specific  for  the
examined brain regions and are not affected by a systemic change and/or an altered permeability of
the  blood-brain  barrier.  Our  results  on  5-month-old  3-NP-treated  animals  resemble  those  from
studies of 3-month-old transgenic YAC128 animals (Mazarei et al. 2013), which is known to be one
of the best animal strains for the modeling of the alterations in human HD (Slow 2003; Pouladi et
al. 2013). The increase observed in the KYN/TRP ratio is comparable with the previous finding of
increased  IDO-1  activity  in  the  brain  (but  not  the  serum)  of  YAC128  animals,  an  alteration
reflecting that observed in several neurodegenerative diseases and their animal models (Vécsei et al.
2013), and suggested to contribute to the neurodegenerative process. The similarity of the findings
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of the KP alterations in this 3-NP model with those observed previously in genetic models (and
especially the YAC128 model) lead us to presume  that the KP alterations observed in transgenic
animals might be secondary to a mitochondrial dysfunction as present in the pathogenesis of HD,
and that 3-NP toxicity may comprise a useful and cheap tool with which to screen the efficacy of
potential drug candidates before the application of more demanding genetic models.
The rationale of our study was to find a valuable biomarker for therapeutic studies in the widely
applied  subacute  3-NP  model  of  HD  with  previously  demonstrated  neurodegenerative
characteristics, at a time point when merely minor behavioral alterations persist. Accordingly, we
were  confirmed that the behavioral alterations evoked by 3-NP toxicity are mostly intermittent,
similarly as observed previously by others,  which suggests that  these alterations might  be only
functional and do not reflect the long-term effects of delayed-type neurodegeneration. On the other
hand, at this delayed time point, we detected a marked persistent increases in the KYN/TRP ratio in
the striatum, hippocampus, cerebellum and brainstem and a slight reduction in the level of 3-OHK
in the cerebellum. Such alterations have not been reported earlier in 3-NP studies and are similar to
those seen in young genetic animal models (especially in 3-month-old YAC128 transgenic mice). In
the era of advanced genetic models of HD, our findings demonstrate the continued relevance and
applicability  of  toxin  models,  which  may  provide  cost-effective  and  rapid  ways  of  screening
potential drug candidates to treat this currently intractable disease.
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8. Figure legends
Fig. 1 Schematic depiction of the kynurenine pathway of the tryptophan metabolism.
Fig. 2 Chromatograms of the analyzed compounds of the kynurenine pathway of the tryoptophan
metabolism,  from C57Bl/6 murine brain samples.  KYNA kynurenic acid,  TRP tryptophan,  KYN
kynurenine,  3-NLT 3-nitro-L-tyrosine,  3-OHK 3-hydroxykynurenine,  IPR isoproterenol,  FLD
fluorescent detector, ECD electrochemical detector
Fig. 3 The effects of 3-NP treatment on different behavioral parameters in C57Bl/6 mice. Shortly
after the last 3-NP injection, the latency to fall was significantly decreased in the rotarod test (A),
but this difference had disappeared 9 days later. The Y-maze test, performed 9 days after the last 3-
NP injection, did not reveal any difference between the groups (B). In the open-field paradigm 3
days after the last 3-NP injection, the ambulation distance was significantly decreased in the total
15-min examination period (C) and in the last 5-min period (E). However, 11 days after the last 3-
NP injection, the difference was significant only in the last 5 min. No difference in rearing time was
detected (D, F). The gray area indicates the 3-NP treatment period.
3-NP mice: n = 16, control mice: n = 14; data are means ± S.E.M; 3-NP 3-nitropropionic acid, LTF
latency to fall, * p < 0.05, ** p < 0.01, *** p < 0.001
Fig. 4 The effects of 3-NP treatment on the KYN/TRP ratio in the serum and different brain regions
of C57Bl/6 mice.  The KYN/TRP ratio was significantly elevated in the striatum, hippocampus,
cerebellum and brainstem of the 3-NP-treated mice. The increase in the cortex did not reach the
level of statistical significance. No alteration was observed in the serum. Data are means ± S.E.M;
3-NP 3-nitropropionic acid, KYN kynurenine, TRP tryptophan, * p < 0.05, ** p < 0.01
